NCT06538623已完成2 期
Single-arm, Open-label Clinical Study of Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-Fluorouracil/Leucovorin (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer After First-line Therapy Failure With AG Regimen
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- OS
研究概览
简要总结
The study explores the efficacy and safety of oxaliplatin combined with irinotecan liposome injection II via hepatic arterial infusion (HAIC) followed by sequential treatment with 5-FU/LV (HAIC) or oral administration of S-1 in patients with liver metastasis from pancreatic cancer after the failure of first-line treatment with the AG regimen. This research aims to accumulate more clinical evidence and treatment options for second-line therapy in metastatic pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years and above, with no gender restrictions;
- •Pathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium), with clinical records indicating metastatic pancreatic cancer, with metastasis limited to the liver;
- •Clinical records indicating previous failure of standard AG treatment (having received at least one cycle of standardized chemotherapy, with disease progression or intolerance during treatment, or disease progression after the end of treatment);
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;
- •Adequate organ function, meeting the following criteria:
- •a. Hematological tests:
- •Neutrophils ≥ 1.5 × 10⁹ /L;
- •White blood cells ≥ 3.0 × 10⁹ /L;
- •Platelets ≥ 85 × 10⁹ /L;
- •Hemoglobin ≥ 70 g/L; b. Biochemical tests:
- •Total bilirubin ≤ 2× upper limit of normal (ULN) (for subjects with biliary obstruction, after biliary drainage ≤ 2.5 × ULN);
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in metastatic subjects ≤ 5 × ULN;
- •Albumin level ≥ 28 g/L;
- •Creatinine clearance rate ≥ 60 ml/min; c. Cardiac function tests:
- •Normal electrocardiogram (ECG) or ECG abnormalities deemed clinically insignificant by the investigator;
- •Left ventricular ejection fraction (LVEF) ≥ lower limit of normal;
- •At least 3 weeks post-surgery, radiotherapy, chemotherapy, or other anti-tumor treatments, with general physical condition or related adverse reactions having recovered (toxicity ≤ grade 1) or stabilized;
- •Willing to participate and sign the informed consent form;
- •Good compliance and agreement to cooperate with survival follow-up.
排除标准
- •Metastatic pancreatic cancer with metastasis to organs other than the liver;
- •Subjects with ascites requiring clinical intervention (including moderate to large amounts of ascites; subjects with ascites need to be stable for more than 4 weeks after drainage);
- •Clinically severe gastrointestinal diseases (including bleeding, infectious inflammation, perforation, obstruction, or diarrhea greater than grade 1);
- •NRS pain score ≥ 4 after standardized treatment with analgesics;
- •Second primary malignancy within 5 years (except cured carcinoma in situ, basal cell, or squamous cell skin cancer; subjects with other previous tumors can be enrolled if there has been no recurrence within 5 years);
- •Uncontrolled cardiovascular or cerebrovascular diseases with clinical symptoms, including but not limited to: ① NYHA class III or higher heart failure; ② unstable angina; ③ myocardial infarction or stroke within 6 months; ④ supraventricular or ventricular arrhythmias requiring treatment or intervention; ⑤ uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg despite optimal treatment);
- •Known active hepatitis B subjects (HBsAg positive and HBV DNA ≥ 10³ copies or ≥ 1000 U/ml);
- •Active infection or unexplained fever > 38.5°C during the screening period or on the day of administration (subjects with fever caused by tumors can be enrolled as judged by the investigator), which, in the investigator's judgment, would affect the subject's participation in this trial or interfere with the evaluation of efficacy;
- •Known allergy to any components of irinotecan hydrochloride liposome, other liposomes, oxaliplatin, 5-FU, LV, or S-1;
- •Pregnant or breastfeeding women;
- •Women of childbearing potential with a positive blood (urine) pregnancy test during the screening period (both male and female subjects should use reliable contraception during the trial and for 3 months after the last dose to prevent pregnancy);
- •Subjects with other medical or social issues that, in the investigator's judgment, might affect their ability to sign informed consent, participation in the trial, or interpretation of the trial results;
- •Patients with an estimated survival time of ≤ 3 months are not included in this study.
研究组 & 干预措施
Liposome Irinotecan Injection II via Hepatic Arterial Infusion Group
Experimental
Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m² Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC); S-1: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
干预措施: Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin (Drug)
Liposome Irinotecan Injection II via Hepatic Arterial Infusion Group
Experimental
Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m² Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC); S-1: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
干预措施: Tegodor (Drug)
结局指标
主要结局
OS
时间窗: From enrollment to the death from any cause, assessed up to 18 months
Overall Survival
次要结局
- PFS(From enrollment to tumor progression or date of death from any cause, whichever came first, assessed up to 18 months)
- ORR(From enrollment to tumor response or date of death from any cause, whichever came first, assessed up to 18 months)
研究者
Zhongmin Wang
Principal Investigator
Ruijin Hospital
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Irinotecan Liposome in Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT04796948Jiangsu HengRui Medicine Co., Ltd.41
已完成
1 期
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasChildhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisChildhood Immunoblastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Liver CancerRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway GliomaRecurrent Colon CancerRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent MelanomaRecurrent Nasopharyngeal CancerRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00101270National Cancer Institute (NCI)24
尚未招募
2 期
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without AddebelizumabNeoadjuvant ChemotherapyResectable Pancreatic CancerNCT06172036Zhejiang University180
已完成
4 期
Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal CancerStage-Ⅱ Colorectal CancerNCT02284529Sinphar Pharmaceutical Co., Ltd20
已完成
1 期
Combination Chemotherapy in Treating Young Patients With Advanced Solid TumorsChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal TumorChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorUnspecified Childhood Solid Tumor, Protocol SpecificNCT00281944National Cancer Institute (NCI)42